Participating Faculty: Best Practices for Treating Parkinson's Disease: A Focus on Symptoms and Considerations for Managed Care

Supplements and Featured Publications, Best Practices for Treating Parkinson’s Disease: A Focus on Symptoms and Considerations for Manage, Volume 18, Issue 7 Suppl

This supplement to The American Journal of Managed Care reviews the economic and quality of life burden associated with Parkinson’s disease (PD). The rationale behind the early diagnosis and treatment of PD is also discussed, with a focus on recognition of nonmotor symptoms of PD and the implications for early therapeutic intervention.This supplement was supported by UCB, Inc.

FacultyDeborah F. Boland, DO, MSPT

Fellow

Movement Disorders Center

Division of Neurology

Department of Medicine

Duke University

Durham, North Carolina

Daniel L. Murman, MD, MS, FAAN

Director of Behavioral and Geriatric Neurology Program

Associate Professor

Department of Neurological Sciences

University of Nebraska Medical Center

Omaha, Nebraska

Fernando L. Pagán, MD

Director of Movement Disorders Program

Associate Professor of Neurology

Department of Neurology

Georgetown University Hospital

Washington, DC

Mark Stacy, MD

Professor of Neurology

Vice Dean for Clinical Research

Division of Neurology

Department of Medicine

Duke University

Durham, North Carolina

Disclosures

These faculty report relationships with the following organizations:

Fernando L. Pagán, MD

Consultant/advisory board: Allergan, Avanir, GlaxoSmithKline, Ipsen, Medtronic, Teva Neuroscience, US WorldMeds

Grants: Medtronic, Teva Neuroscience

Mark Stacy, MD

Consultant: Allergan, Chelsea, General Electric, GlaxoSmithKline, Merck, Merz, Neuronova, Novartis, Noven, Osmotica, SK Life Sciences, Teva, UCB Grant/research support: Ceregene, IMPAX, Michael J. Fox Foundation, National Institutes of Health, Novartis, Parkinson Study Group

Protocol steering committee: Allergan, EMD Serono, Teva

Royalties: Informa Press (publisher of Handbook of Dystonia)

Safety monitoring board: Neurologix

Deborah F. Boland, DO, MSPT, and Daniel L. Murman, MD, MS, FAAN, report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.